Boyu Zhong

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie et al. · Investigational New Drugs · 2012 · 159 citations · Full text

Asymmetric Synthesis of Chiral Organofluorine Compounds:  Use of Nonracemic Fluoroiodoacetic Acid as a Practical Electrophile and Its Application to the Synthesis of Monofluoro Hydroxyethylene Dipeptide Isosteres within a Novel Series of HIV Protease Inhibitors

Andrew G. Myers, J. Kent Barbay, Boyu Zhong · Journal of the American Chemical Society · 2001 · 140 citations

Synthesis of highly epimerizable N-protected α-amino aldehydes of high enantiomeric excess

Andrew G. Myers, Boyu Zhong, Mohammad Movassaghi et al. · Tetrahedron Letters · 2000 · 99 citations

Engineering, Biochemistry, Organic Chemistry +7

Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases

Chafiq Hamdouchi, Boyu Zhong, J. S. MENDOZA et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 90 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Drug Target +12

Preparation of Chiral, <i>C</i>-Protected α-Amino Aldehydes of High Optical Purity and Their Use as Condensation Components in a Linear Synthesis Strategy

Andrew G. Myers, Daniel W. Kung, Boyu Zhong et al. · Journal of the American Chemical Society · 1999 · 46 citations

Engineering, Linear Synthesis Strategy, Biochemistry +12